Quantum-Si Incorporated Class A Common Stock (QSI)

FairStock Score: 56/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett-Graham investor, I start with business quality and owner earnings. Quantum-Si sells instruments and consumables for next-generation protein sequencing, but the figures show a commercial story still in its infancy. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was only $344,000, while net income was -$23.5M. For FY2025, revenue was $2.4M and net income was -$101.3M; FY2024 revenue was $3.1M with a -$101.0M loss. That is not a compounding machine yet. The revenue trend is moving the wrong way: fiscal Q2 2026 revenue fell from $591,000 in fiscal Q2 2025. Free cash flow is -$93.7M trailing, a -30.5% FCF yield against a $307.1M market cap at the 2026-10-13 close of $1.41. The balance sheet has little debt, with D/E of 0.02, and an Altman Z-score of 8.63, so solvency pressure may not be immediate. FairStock calculations put P/E at -3.07, P/B at 1.72, ROE at -49.11%, ROCE at -25.71%, and Piotroski at 4/9. There is no Lynch category because the company lost money in each of the last four years. I see a proprietary technology claim, but no demonstrated moat in revenue or profits. Until revenue inflects and cash burn shrinks, the stock is a lottery ticket, not a Graham bargain.

In plain English: Quantum-Si makes laboratory tools for studying proteins. The business looks weak right now: sales are tiny and it loses a lot of money, with no profits in recent years. At $1.41, the price looks expensive compared with the current business numbers and depends on future success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer